Market/Novel Tech Articles
Novartis announces spin out of Alcon unit to consolidate focus on pharmaceutical products.
Novartis AG (NYSE:NVS; SIX:NOVN), a Swiss-based biopharmaceutical company, has announced its intention to spin out its Alcon eye care business but will retain the pharmaceutical ophthalmology portfolio. The decision comes after a year-long strategic review which examined a number of potential options. Alcon’s surgical and vision care lines are understood to have provided $6.7 billion […]Read full story
Ophthotech Corporation (NASDAQ:OPHT) announce agreements with two US universities to progress gene therapy for autosomal dominant retinitis pigmentosa (adRP)
Ophthotech Corporation (NASDAQ: OPHT), a US-based biopharmaceutical company focused on the development of retinal disease therapies, has announced the execution of agreements with both the universities of Florida and Pennsylvania. The company, with a market capitalization of over $110M, aims to access university technology to build novel gene therapies for the treatment of adRP. The […]Read full story
Clearside Biomedical Inc. study fails to show clinical significance of triamcinolone acetonide plus anti-VEGF treatment
Clearside Biomedical Inc. (NASDAQ:CLSD), head-quartered in Alpharetta, Ga., USA, have announced the results of a Phase II clinical study investiagting the use of triamcinolone acteonide (CST-TA), with and without aflibercept for the treatment of diabetic macular edema (DME). The results of the study showed that patients receiving CST-TA plus aflibercept gained an average of 12.3 […]Read full story